How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Game summary of the San Francisco 49ers vs. Indianapolis Colts NFL game, final score 48-27, from December 22, 2025 on ESPN.

Between the two industry giants, Fidelity’s robust platform pulls slightly ahead Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT).